Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05 2021 - 4:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced two upcoming presentations at the
American Association for Cancer Research (AACR) Annual Meeting
2021, which will be held virtually from April 10-15, 2021 and May
17-21, 2021. These presentations will describe the discovery of
Arvinas’ two clinical-stage PROTAC degraders, ARV-110 and ARV-471,
including the first disclosures of their structures.
Details for the presentations are as follows:
Title: Discovery of ARV-110, a first in class
androgen receptor degrading PROTAC® for the treatment of men with
metastatic castration resistant prostate cancerDate and
Time: April 11, 2021 from 2:05 PM - 2:15 PM
ETPresenter: Lawrence B. Snyder, Ph.D., Executive
Director of Medicinal Chemistry at ArvinasSession
Title: New Therapeutics Targeting Molecular Drivers in
Cancer
Title: The discovery of ARV-471, an orally
bioavailable estrogen receptor degrading PROTAC® for the treatment
of patients with breast cancerDate and Time: April
11, 2021 from 2:20 PM - 2:30 PM ETPresenter:
Lawrence B. Snyder, Ph.D., Executive Director of Medicinal
Chemistry at Arvinas Session Title: New
Therapeutics Targeting Molecular Drivers in Cancer
Abstracts will be available for registered attendees on the AACR
website beginning on April 9, 2021.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Contacts for
ArvinasInvestorsWill O’Connor, Stern
Investor Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024